NCT06098651View on ClinicalTrials.gov

A Study of DCR-STAT3 in Adults With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

August 14, 2023

Primary Completion Date

September 17, 2025

Study Completion Date

September 17, 2025

Conditions
Solid Tumor, AdultRefractory Tumor
Interventions
DRUG

DCR-STAT3

DCR-STAT3 is a sterile, preservative-free solution in WFI that will be diluted in a suitable admixture diluent (0.9% normal saline) prior to IV infusion.

Trial Locations (2)

75039

Next Oncology, Dallas

78229

Next Oncology, San Antonio

All Listed Sponsors
lead

Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

INDUSTRY